Answers are grounded in this paper and cite their sources.
Objective: To evaluate the in vitro cytotoxicity of a madecassoside-loaded ultra-small unilamellar nanocarrier system (MU) against keloid-derived fibroblasts and to compare it with that of the empty carrier and pure madecassoside. Design: In vitro experimental study using keloid-derived fibroblasts and the MTT colorimetric assay; each treatment was performed in triplicate. Intervention: MU, prepared from virgin coconut oil (VCO), soy lecithin and Tween 80 by sonication-aided emulsification, its empty carrier and pure madecassoside were applied to the cells at 10, 20, 30 and 40 µg/mL for 72 h. Main outcome measures: Cell viability (percentage of untreated control), the half-maximal inhibitory concentration (IC50) calculated by semilogarithmic linear regression, and cell morphology under an inverted microscope. Groups were compared by two-way ANOVA with Bonferroni post hoc test. Results: MU reduced fibroblast viability in a concentration-dependent manner, with an IC50 of 29.77 µg/mL compared with 58.21 µg/mL for the empty carrier and 78.80 µg/mL for pure madecassoside (the latter two extrapolated beyond the highest tested concentration). At 30 µg/mL, viability after MU treatment was significantly lower than after pure madecassoside (65.1% vs 104.4%; p < 0.05). MU was the only sample that reduced viability below 50% within the tested range. Conclusion: Loading madecassoside into the ultra-small unilamellar nanocarrier increased its cytotoxic potential against keloid fibroblasts, as reflected by an approximately 2.6-fold lower IC50 than that of pure madecassoside, with the carrier itself contributing partly to this effect.
No takes yet. Share an insight, caveat, or question.
Chairunisa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: